Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Dense Carboplatin, Taxotere, and Herceptin in Breast Cancer
NCT00232479Phase 2Completed
- Sponsor
- University of Miami
- Start
- Sep 2005
- Primary completion
- May 2008
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, docetaxel and carboplatin in breast cancer, sponsored by University of Miami. Primary endpoint: Pathologic Complete Response at 16 weeks. Started Sep 2005; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00232479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232479.